XM tidak memberikan layanan kepada penduduk Amerika Serikat.
B
B

BayerAG


Berita

BASF to prepare agricultural business for IPO, Bloomberg reports

UPDATE 3-BASF to prepare agricultural business for IPO, Bloomberg reports Adds details on new CEO in paragraph 12, on batteries business in paragraph 13 FRANKFURT, Sept 18 (Reuters) - BASF BASFn.DE plans to prepare its agricultural chemicals business for an initial public offering in the next few years as part of restructuring measures set to be announced by the group this month, Bloomberg News reported on Wednesday.
B
B
C

Bayer, others defeat US farmers' chemical price-fixing lawsuit

Bayer, others defeat US farmers' chemical price-fixing lawsuit By Mike Scarcella Sept 16 (Reuters) - A U.S. judge has dismissed a lawsuit accusing agriculture giants Bayer, Corteva, Syngenta and others of conspiring with wholesalers and retail outlets to fix prices for seeds and crop protection chemicals, causing farmers to pay higher prices. St. Louis-based U.S.
B
B
C

Bayer AG Says Darolutamide Plus Adt Significantly Reduced Risk Of Radiological Progression Or Death Compared To Placebo Plus Adt In Patients With Mhspc

BRIEF-Bayer AG Says Darolutamide Plus Adt Significantly Reduced Risk Of Radiological Progression Or Death Compared To Placebo Plus Adt In Patients With Mhspc Bayer AG BAYGn.DE : BAYER AG SAYS DAROLUTAMIDE PLUS ADT SIGNIFICANTLY REDUCED RISK OF RADIOLOGICAL PROGRESSION OR DEATH COMPARED TO PLACEBO PLUS ADT IN PATIENTS WITH MHSPC Source text for Eiko
B

Jury rules in favor of Bayer's Monsanto in Philadelphia trial over Roundup

Jury rules in favor of Bayer's Monsanto in Philadelphia trial over Roundup Sept 11 (Reuters) - Bayer's BAYGn.DE Monsanto unit said on Wednesday that a Philadelphia Court jury reached a verdict in the Young Roundup product liability trial in their favor. Bayer bought Monsanto for $63 billion in 2018, and has faced extensive and costly litigation over whether Monsanto's Roundup weed killer causes cancer.
B

Bayer Says Jury Finds In Favor Of Monsanto In Philadelphia Trial

BRIEF-Bayer Says Jury Finds In Favor Of Monsanto In Philadelphia Trial Sept 11 (Reuters) - Bayer AG BAYGn.DE : JURY FINDS IN FAVOR OF MONSANTO IN PHILADELPHIA TRIAL BAYER AG: JURY REACHED VERDICT IN YOUNG ROUNDUP PRODUCT LIABILITY TRIAL BEFORE JUDGE ANGELO FOGLIETTA IN PHILADELPHIA COURT OF COMMON PLEAS. BAYER AG - WILL CONTINUE SUPPORTING LEGISLAT
B

Bayer Issues 750 Million Euro Hybrid Bond

BRIEF-Bayer Issues 750 Million Euro Hybrid Bond Sept 10 (Reuters) - BAYER AG BAYGn.DE : ISSUES 750 MILLION EURO HYBRID BOND SINGLE TRANCHE WITH A NON-CALL PERIOD OF 5.25 YEARS, COMBINED WITH A TENDER OFFER FOR ONE OF BAYER’S EXISTING HYBRID BONDS BAYER INTENDS TO LIST THE HYBRID BONDS ON THE LUXEMBOURG STOCK EXCHANGE THE PROCEEDS WILL BE USED FOR
B

European companies cut jobs as economy sputters

RPT-FACTBOX-European companies cut jobs as economy sputters Repeats with no changes to text to add 'Factbox' tag in headline Sept 10 (Reuters) - Elevated levels of inflation and the impact of the war in Ukraine have forced companies across Europe to freeze hiring or cut jobs. Here are some of the layoffs announced since the start of June: BANKS * DNB DNB.OL : The Norwegian lender said on Sept.
B
I
U
V
U

European companies cut jobs as economy sputters

European companies cut jobs as economy sputters Adds DNB Sept 10 (Reuters) - Elevated levels of inflation and the impact of the war in Ukraine have forced companies across Europe to freeze hiring or cut jobs. Here are some of the layoffs announced since the start of June: BANKS * DNB DNB.OL : The Norwegian lender said on Sept. 10 it would cut the equivalent of 500 full-time jobs over the next six months, as it prepares for lower interest rates and tougher competition ahead.
B
I
U
V
U

Bayer: Analysis From HF Reveals Patients Receiving Finerenone Have Reduced Risk Of New-Onset Diabetes

BRIEF-Bayer: Analysis From FINEARTS-HF Reveals Patients Receiving Finerenone Have Reduced Risk Of New-Onset Diabetes Sept 10 (Reuters) - BAYER AG BAYGn.DE : NEW SUBGROUP ANALYSIS FROM FINEARTS-HF REVEALED PATIENTS WITH HEART FAILURE AND A LEFT VENTRICULAR EJECTION FRACTION OF ≥40% RECEIVING FINERENONE HAD A REDUCED RISK OF NEW-ONSET DIABETES Furt
B

Bayer Reports Preliminary Efficacy Results for BAY 2927088 in Phase I/ 01 Study

BRIEF-Bayer Reports Preliminary Efficacy Results for BAY 2927088 in Phase I/ II SOHO-01 Study Sept 10 (Reuters) - BAYER AG BAYGn.DE : SAID ON MONDAY: NEW RESULTS FOR INVESTIGATIONAL AGENT BAY 2927088 IN HER2-MUTANT NON-SMALL CELL LUNG CANCER PRESENTED ENCOURAGING RESULTS FROM EXPANSION PART OF ONGOING PHASE I/II SOHO-01 STUDY EVALUATING THE SAFETY
B

Bayer's Eye Drug Pre-Filled Syringes Approved In EU

BRIEF-Bayer's Eye Drug Pre-Filled Syringes Approved In EU Sept 9 (Reuters) - Bayer AG BAYGn.DE : EYLEA™ 8 MG PRE-FILLED SYRINGE APPROVED IN EU GERMANY WILL BE ONE OF FIRST MARKETS TO LAUNCH NEW PRE-FILLED SYRINGE Further company coverage: BAYGn.DE (Gdansk Newsroom)
B

Bayer to Present New Prostate Cancer Data and Continued Oncology Portfolio

BRIEF-Bayer to Present New Prostate Cancer Data and Continued Oncology Portfolio Sept 4 (Reuters) - BAYER AG BAYGn.DE WILL PRESENT PRIMARY RESULTS FROM THE PHASE III ARANOTE TRIAL IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) FOR NUBEQA(®)(DAROLUTAMIDE) AS A LATE-BREAKING ORAL PRESENTATION WILL PRESENT PRIMARY RESULTS FROM THE EUROPEAN O
B

VW row flags Germany’s creaking corporate model

BREAKINGVIEWS-VW row flags Germany’s creaking corporate model The author is a Reuters Breakingviews columnist. The opinions expressed are his own. By Pierre Briancon BERLIN, Sept 5 (Reuters Breakingviews) - A company whose chief financial officer says it only has “one, maybe two” years to turn around its core brand must have done something wrong.
B
B
T
V

Bayer To Unveil New Data From Its Phase III Oasis 3 Long-Term Study Of Elinzanetant

BRIEF-Bayer To Unveil New Data From Its Phase III Oasis 3 Long-Term Study Of Elinzanetant Sept 4 (Reuters) - BAYER AG BAYGn.DE : TO UNVEIL NEW DATA FROM ITS PHASE III OASIS 3 LONG-TERM STUDY OF ELINZANETANT IN TREATMENT OF VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE BAYER WILL PRESENT DETAILED RESULTS SEPTEMBER 10 - 14 Further company coverage: [B
B

European companies cut jobs as economy sputters

FACTBOX-European companies cut jobs as economy sputters Adds Telia Sept 4 (Reuters) - Elevated levels of inflation and the impact of the war in Ukraine have forced companies across Europe to freeze hiring or cut jobs. Here are some of the layoffs announced since the start of April: BANKS * TSB: The British bank owned by Spain's Sabadell SABE.MC is seeking 250 job cuts, its spokesperson and employee union said on May 8. INDUSTRIALS AND ENGINEERING * PKP CARGO PKPP.WA : Poland's largest freight co
B
B
B
C
I
N
T
T
U
V
B
U

US will still pay at least twice as much after negotiating drug prices

UPDATE 1-US will still pay at least twice as much after negotiating drug prices U.S. pays higher drug prices, gets priority access Medicare's negotiated prices most significant for drugs with little competition Goal is to balance affordability and innovation Updates first graphic to align colors representing countries with second graphic By Deena Beasley Sept 3 (Reuters) - The U.S.
A
A
B
N
P

Bayer: Bluerock Gets FDA Clearance Of Application For Photoreceptor Diseases Treatment

BRIEF-Bayer: Bluerock Gets FDA Clearance Of Application For Photoreceptor Diseases Treatment Sept 3 (Reuters) - Bayer AG BAYGn.DE : BLUEROCK THERAPEUTICS ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR INVESTIGATIONAL IPSC-DERIVED CELL THERAPY OPCT-001 FOR TREATMENT OF PRIMARY PHOTORECEPTOR DISEASES Further company coverage: [BAYGn.DE] (Gdansk Newsr
B

US will still pay at least twice as much after negotiating drug prices

ANALYSIS-US will still pay at least twice as much after negotiating drug prices U.S. pays higher drug prices, gets priority access Medicare's negotiated prices most significant for drugs with little competition Goal is to balance affordability and innovation By Deena Beasley Sept 3 (Reuters) - The U.S. government's first-ever negotiated prices for prescription drugs are still on average more than double, and in some cases five times, what drugmakers have agreed to in four other high-income count
A
A
B
N
P

Bayer rises after positive kidney drug study in heart failure

CORRECTED-BUZZ-Bayer rises after positive kidney drug study in heart failure Corrects trial name in 2nd bullet; updates share performance in 1st and 5th bullet ** Shares in Bayer BAYGn.DE rise 0.6% after the German firm said its kidney drug Kerendia helped patients avoid complications from a common form of heart failure ** The late-stage FINEARTS-H
B
G

Bayer Shares Finerenone Update

BRIEF-Bayer Shares Finerenone Update Sept 2 (Reuters) - BAYER AG BAYGn.DE : SAID ON SUNDAY FINERENONE SHOWED SIGNIFICANT IMPROVEMENT IN CARDIOVASCULAR OUTCOMES IN ADULTS WITH COMMON FORM OF HEART FAILURE WITH HIGH UNMET MEDICAL NEED Source text for Eikon: ID:nNDL72qgt8 Further company coverage: [BAYGn.DE] (Gdansk Newsroom)
B



Kondisi

Aset Populer

Pengungkapan: Entitas XM Group menyediakan layanan khusus eksekusi dan akses ke Fasilitas Trading Online kami, yang memungkinkan Anda untuk melihat dan/atau menggunakan konten yang tersedia pada atau melalui situs, yang tidak untuk mengubah atau memperluas, serta tidak mengubah atau memperluas hal tersebut. Akses dan penggunaan ini selalu sesuai dengan: (i) Syarat dan Ketentuan; (ii) Peringatan Risiko; dan (iii) Pengungkapan Penuh. Oleh karena itu, konten disediakan hanya sebagai informasi umum. Anda juga harus ketahui bahwa konten Fasilitas Trading Online kami bukan sebagai ajakan atau tawaran untuk untuk melakukan transaksi apa pun di pasar finansial. Trading di pasar finansial mana pun melibatkan tingkat risiko yang signifikan pada modal Anda.

Semua materi yang diterbitkan di Fasilitas Trading Online kami hanya untuk tujuan edukasi/informasi dan tidak boleh mengandung nasihat dan rekomendasi finansial, pajak investasi atau trading, catatan harga trading kami, penawaran, permintaan, transaksi dalam instrumen finansial apa pun atau promo finansial untuk Anda yang tidak diminta.

Konten pihak ketiga apa pun, serta konten yang disiapkan oleh XM, seperti opini, berita, riset, analisis, harga, informasi lain atau link ke situs pihak ketiga yang tersedia "sebagaimana adanya", sebagai komentar pasar umum dan bukan menjadi nasihat investasi. Sejauh konten apa pun ditafsirkan sebagai penelitian investasi, Anda harus memperhatikan dan menerima bahwa konten tersebut tidak dimaksudkan dan belum disiapkan sesuai dengan persyaratan hukum yang dirancang untuk mempromosikan kemandirian riset investasi dan dengan demikian akan dianggap sebagai komunikasi pemasaran di bawah hukum dan peraturan yang relevan. Mohon dipastikan bahwa Anda telah membaca dan memahami Notifikasi pada Riset Investasi Non-Independen dan Peringatan Risiko kami mengenai informasi di atas, yang dapat diakses disini.

Peringatan Resiko: Modal Anda beresiko. Produk dengan leverage mungkin tidak cocok bagi semua orang. Silahkan pertimbangkan Pengungkapan Resiko kami.